Category: Cancer Treatments
A Vaccine That Defeats Cancerous Tumor’s Defenses Offers a New Path to Curing Cancer
Key Takeaways: Tumors evade immune detection by shedding MICA/MICB proteins from immune cells, allowing them to hide and proliferate. A new vaccine boosts MICA/MICB protein density on immune cells, …
Immunotherapy Transforms Melanoma Outcomes: French Study Highlights Progress, Challenges, and Key Survival Data
Key Takeaways: Dual immunotherapy (anti-PD-1 + anti-CTLA-4) achieves 77% survival at 6.5 years in metastatic melanoma, compared to 69% with anti-PD-1 alone. Combination therapy boosts efficacy but increases severe …
Scientists Design Nanoparticles to Help Immune Cells Accurately Target Pathogens without Causing Harm to Healthy Cells
According to reports, there were about 190000 cases and 75000 mortality from acute lung injury and acute respiratory distress syndrome ALI/ARDS. With the advent of COVID-19, these figures skyrocketed …
Breaking Through Cancer’s Defenses: Genetic Engineering of T-cells for Effective Tumors Targeting
Key Takeaways CAR T-cell therapy genetically modifies a patient’s T-cells to recognize and destroy cancer, offering personalized treatment for aggressive blood cancers like lymphomas and leukemias. Approved for select …
Dostarlimab (Jemperli) Cures Colorectal Cancer without the Need for Surgery or Chemotherapy
A small clinical trial with 12 participants yielded impressive results: 100% of the colorectal cancer patients saw their cancer disappear. So how does this immunotherapy-based treatment work so effectively? …New Study Could Help Improve Prevention and Treatment of Deadly Gliomas
Key Takeaways Genetic Link to Gliomas – Researchers identified a DNA alteration (rs55705857) that increases glioma risk and speeds up tumor growth. Faster Tumor Development – In animal models, …Durvalumab (Imfinzi) Boosts Survival in Early-Stage Lung Cancer: What Patients Should Know
Key Takeaways: Adding Durvalumab (Imfinzi) to chemotherapy before and after surgery significantly improves outcomes for early-stage non-small cell lung cancer (NSCLC). Patients receiving Durvalumab had a 73% chance of …